CD24 and medical procedure: Ever since Al-Hajj et al. reported that CD44+/CD24−/low cells were more tumorigenic than CD44+/CD24+ cells in the breast cancer7, CD44+/CD24−/low has been widely accepted as a CSC marker and predictor for the prognosis of breast cancer15,16.